Team leader

Presentation

Chronic kidney diseases (CKD) are a growing health problem worldwide as they lead to renal failure with so far limited treatment options. Approximately 10% of the general population have renal insufficiency, of which 5.6% at a light or moderate stage, 3.7% at a severe stage and 0.13% at the terminal stage needing dyalisis or transplantation as replacement therapy. CKD can be caused by disorders such as glomerulonephritis (GN). Among the GN, IgA nephropathy (IgAN), Lupus nephritis (LN) and idiopathic nephrotic syndrome (INS) are major causes of end-stage renal disease worldwide. Understanding mechanisms leading to IgAN, LN or INS are crucial to design new therapeutic strategies.  Our team is one of the world leaders in IgAN field (www.iigann.com). We described that a soluble form of the CD89 (sCD89), an IgA Fc receptor, is part of nephritogenic mesangial IgA deposits and identified the Transferrin Receptor 1 (TfR1) as the IgA1 mesangial receptor in IgAN. We also showed that the TfR1 binds to IgA1 in a physiological way, promoting erythroblast proliferation. In IgAN physiopathology, TfR1 is overexpressed on mesangial cells with preferential affinity for deglycosylated IgA1 and induces proliferation of mesangial cells via the PI3K/Akt pathway, and production of inflammatory cytokines via the MAPK/Erk pathway. In other studies, we have shown that abnormalities  of  IgA1  glycosylation,  a  galactose-­‐deficient  (Gd)  IgA1,  also  arise  in  alcoholic  cirrhosis  (AC),  including mesangial IgA deposits with possible development of secondary IgAN indicating that common environmental factors (such as bacteria translocation at portal vein) may influence the IgAN development6. Moreover, we developed a new humanized  mouse  model  of  IgAN:  alpha1KI-CD89Tg  mice,  in  which  sCD89  plays  a  pivotal  role  in  IgAN  inducing  the formation of mesangial nephritogenic deposits, mesangial TfR1 and transglutaminase 2 (TG2) overexpression. Ablation of TG2 gene resulted in protection from the disease, showing for the first time that TG2 plays a crucial role in IgAN development. We have also studied the mechanisms involved in celiac disease (CD) and showed similarities with IgAN. In collaborative studies,  we  showed  an  increase  of  IgA  complexes  containing  a  gliadin peptide and apical expression of TfR1 on enterocytes in active CD patients. This overexpression could allow the retrograde transcytosis of gliadin peptide from apical to basal side of enterocytes. Moreover, we demonstrated that gluten sensitivity in mice leads to a CD phenotype, associated with overexpression of TfR1 and TG2, as well as overproduction of IgA and that it exacerbates IgAN.

Concerning our fundamental research on immunoregulation through Fc receptors (FcRs), we have shown, in a tight consortium with the team of U. Blank in the research unit, that CD89 (FcalphaRI), CD16 (FcgammaRIII) and CD32A (FcgammaRIIA), all receptors containing immunoreceptor tyrosine-based activation motifs (ITAM), are switch molecules which can induce either inhibition or cell activation, depending on their ligand configuration  (mono/divalent versus multivalent) leading to inhibition (ITAMi) or activation (ITAMa), respectively. Targeting CD89 inhibited the appearance of inflammation in lungs, joints and  kidneys. IVIg also induces  ITAMi-mediated  inhibition  through  CD16A  and  CD32A  for  IVIgG  or through CD89 for IVIgA. In another hand, we have shown that E Coli is able to directly bind to CD16 and induce an ITAMi-mediated inhibition of phagocytosis, allowing E coli to escape the immune system. Our recent studies have shown that CD89 acts an innate receptor for bacteria that protects from sepsis through ITAMa-signaling pathway.

Our studies include 5 work-packages:

WP1. Understanding physiopathology of IgAN:

  1. To determine the role of the transglutaminase 2 in IgAN and
  2. To characterize the gut-kidney axis in IgAN;

WP2. Identification of autoantibodies in idiopathic nephrotic syndrome;

WP3. Src kinases as pronostic biomarkers in autoimmune GN:

  1. To establish Fyn effectors (phosphorylated SHP-1S591 and PKC-α) as prognostic biomarkers for autoimmune GN and
  2. To identify new specific prognostic markers for GN severity.

WP4. New therapeutic approaches for GN that are currently developped by targeting immunoreceptors as new anti-inflammatory therapeutic approaches in collaboration with an spinoff Inatherys (www.inatherys.com).

WP5. Studies on hypertension and lithium induced renal toxicity.

Team strengths are :

  1. Strong interaction with Bichat and Robert Debré hospitals (Nephrology, Physiology, Immunology).
  2. Available biobanks: 5 different cohorts of patients (Nephrotest, Henoch-Schonlein purpura, INS-nephrochain, GN Bichat, and MicrobIgAN cohorts).
  3. Mouse models of renal diseases (humanized model for IgAN, transgenic, KO mice), kidney-derived primary cells (mesangial cells, podocytes…).
  4. An active partner of the INFLAMEX Labex.